Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment
Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras
Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras
View: Text | PDF
Research Article Oncology

Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment

  • Text
  • PDF
Abstract

Glioblastoma (GBM) is the most aggressive form of glioma with a high rate of relapse despite intensive treatment. Tumor recurrence is tightly linked to radio-resistance, which in turn is associated with hypoxia. Here, we discovered a strong link between hypoxia and local complement signaling using publicly available bulk, single-cell, and spatially resolved transcriptomic data from patients with GBM. Complement component 3 (C3) and the receptor C3AR1 were both associated with aggressive disease and shorter survival in human glioma. In a genetically engineered mouse model of GBM, we found C3 specifically in hypoxic tumor areas. In vitro, we found an oxygen level–dependent increase in C3 and C3AR1 expression in response to hypoxia in several GBM and stromal cell types. C3a induced M2 polarization of cultured microglia and macrophages in a C3aR-dependent fashion. Targeting C3aR using the antagonist SB290157 prolonged survival of glioma-bearing mice both alone and in combination with radiotherapy while reducing the number of M2-polarized macrophages. Our findings establish a strong link between hypoxia and complement pathways in GBM and support a role of hypoxia-induced C3a/C3aR signaling as a contributor to glioma aggressiveness by regulating macrophage polarization.

Authors

Rebecca Rosberg, Karolina I. Smolag, Jonas Sjölund, Elinn Johansson, Christina Bergelin, Julia Wahldén, Vasiliki Pantazopoulou, Crister Ceberg, Kristian Pietras, Anna M. Blom, Alexander Pietras

×

Figure 6

C3AR1 is a possible therapeutic target in GBM.

Options: View larger image (or click on image) Download as PowerPoint
C3AR1 is a possible therapeutic target in GBM.
(A) Illustration (created...
(A) Illustration (created with BioRender.com) of study design for treatment with SB290157 (1 mg/kg) with or without combination with 10 Gy radiotherapy of murine gliomas induced through RCAS-PDGFB and RCAS-shp53 in Nestin/tv-a mice. (B) Kaplan-Meier curve showing the survival of mice treated with vehicle (red, n = 5), SB290157 (blue, n = 4), vehicle + 10 Gy (orange, n = 6), or SB290157 + 10 Gy (green, n = 8) as indicated. (C) Representative image of immunofluorescence staining of macrophages/microglia (F4/80), tumor cells (Olig2), and astrocytes (GFAP) in mice treated as indicated. (D) Quantitative analysis of F4/80+ cells/area (μm2) as indicated (n = 11 for untreated and n = 9 for SB290157 treated). (E) Representative images of immunofluorescence staining of tumor cells (Olig2) and CD206+ macrophages/microglia in mice treated as indicated. (F) Quantitative analysis of CD206+ cells/Area (μm2) as indicated (n = 11 for untreated and n = 9 for SB290157 treated). *P < 0.05, **P < 0.01, or ***P < 0.001. Statistical analysis was performed using the Mann-Whitney U test. Scale bars: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts